AS
AB Science
France - Paris
BiotechnologyFocus: Small Molecules
AB Science is a life sciences company focused on Small Molecules.
OncologyNeurologyImmunologyUnknownRespiratory
Open Jobs
5
Pipeline & Clinical Trials
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
Multiple SclerosisStudy characteristics of adolescents affected by dental caries
Caries,DentalClinical Trials (1)
NCT05935813Caries in Adolescents (Karies Hos Ungdom)
N/AFood Supplement 1
Microbial ColonizationClinical Trials (1)
NCT05524649Effect of Probiotics on Infant's Fecal Microbiota Composition
N/ABerberine incorporated in gamma cyclodextrin
Drug AbsorptionClinical Trials (1)
NCT04918667Effect of Gamma-cyclodextrin on the Bioavailability of Berberine
Phase 114C-AB1010
Healthy VolunteersClinical Trials (1)
NCT05200169Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male Subjects
Phase 1GoodIdea
HealthyClinical Trials (1)
NCT03152682A Study Evaluating Good Idea on Glucose Homeostasis in a Healthy Population
Phase 1HRG80™ Red Ginseng
Drug AbsorptionClinical Trials (1)
NCT04932265Effect of Gamma-cyclodextrin on the Bioavailability of Ginsenosides
Phase 1Phase 1/2
Clinical Trials (1)
NCT05211570AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1/2masitinib
MastocytosisClinical Trials (1)
NCT00831974Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis
Phase 2Masitinib Mesylate
Covid19Clinical Trials (1)
NCT05047783Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
Phase 2masitinib
Rheumatoid ArthritisClinical Trials (1)
NCT00831922Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis
Phase 2Oxytocin
AtrophyClinical Trials (1)
NCT02497547An Efficacy Study of Vagitocin in Postmenopausal Women With Symptoms of Vaginal Atrophy
Phase 2AB1010
AsthmaClinical Trials (1)
NCT00842270Efficacy of Oral AB1010 in Adult Patients With Severe Persistent Corticosteroid Dependent Asthma
Phase 2oral masitinib
Gastro-intestinal Stromal TumoursClinical Trials (1)
NCT00998751Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)
Phase 2Masitinib 4.5 mg/kg/day
Mast Cell Activation SyndromeClinical Trials (1)
NCT05449444Masitinib for the Treatment of Severe Mast Cell Activation Syndrome
Phase 2masitinib
Multiple SclerosisClinical Trials (1)
NCT01450488Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis
Phase 2masitinib
Alzheimer's DiseaseClinical Trials (1)
NCT00976118Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease
Phase 2Masitinib
SARS-CoV 2Clinical Trials (1)
NCT04622865Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
Phase 2Masitinib
PsoriasisClinical Trials (1)
NCT01045577A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis
Phase 2masitinib
Gastro Intestinal Stromal TumorClinical Trials (1)
NCT01506336Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib
Phase 2recombinant human glutamic acid dehydrogenase
Latent Autoimmune Diabetes in Adultsmasitinib
Multiple MyelomaClinical Trials (1)
NCT00866138Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3
Phase 2Emeramide
Mercury PoisoningClinical Trials (1)
NCT02486289Pilot Proof of Concept Study of NBMI Treatment of Mercury Intoxication
Phase 2masitinib
Rheumatoid ArthritisClinical Trials (1)
NCT00913432Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis
Phase 2masitinib
MastocytosisClinical Trials (1)
NCT01266369Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation
Phase 2Masitinib
Colorectal Cancer MetastaticClinical Trials (1)
NCT03556956Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer
Phase 2/3Masitinib
Ovarian CancerClinical Trials (1)
NCT02490488Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients
Phase 2/3Masitinib
Amyotrophic Lateral Sclerosis (ALS)Clinical Trials (1)
NCT02588677Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)
Phase 2/3masitinib 3 mg
Rheumatoid Arthritis (RA)Clinical Trials (1)
NCT01410695Masitinib in Refractory Active Rheumatoid Arthritis
Phase 2/3Masitinib
Pancreatic CancerClinical Trials (1)
NCT00789633Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Phase 3Masitinib
AsthmaClinical Trials (1)
NCT03771040Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels
Phase 3Masitinib
Gastrointestinal Stromal TumorsClinical Trials (1)
NCT01694277Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
Phase 3Masitinib
Alzheimer DiseaseClinical Trials (1)
NCT01872598Masitinib in Patients With Mild to Moderate Alzheimer's Disease
Phase 3Masitinib
Metastatic Colorectal CancerClinical Trials (1)
NCT02605044Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer
Phase 3Masitinib
Multiple MyelomaClinical Trials (1)
NCT01470131A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Phase 3Masitinib
Amyotrophic Lateral SclerosisClinical Trials (1)
NCT03127267Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
Phase 3Masitinib
AsthmaClinical Trials (1)
NCT01449162Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids
Phase 3Masitinib
Metastatic MelanomaClinical Trials (1)
NCT01280565Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
Phase 3Masitinib 4.5 mg/kg/day
Amyotrophic Lateral Sclerosis (ALS)Clinical Trials (1)
NCT07174492Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients
Phase 3Masitinib
Gastro-Intestinal Stromal TumourClinical Trials (1)
NCT02009423Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence
Phase 3Phase 3
Clinical Trials (1)
NCT01433497Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis
Phase 3Masitinib
Indolent Systemic MastocytosisClinical Trials (1)
NCT00814073Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis
Phase 3Masitinib
Gastrointestinal Stromal TumorsClinical Trials (1)
NCT00812240Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
Phase 3Phase 3
Clinical Trials (1)
NCT03761225Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Phase 3Masitinib
Indolent Systemic MastocytosisClinical Trials (1)
NCT04333108Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
Phase 3Phase 3
Clinical Trials (1)
NCT03766295Masitinib Plus Gemcitabine in Pancreatic Cancer
Phase 3Phase 3
Clinical Trials (1)
NCT05441488Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
Phase 3Placebo
Alzheimer DiseaseClinical Trials (1)
NCT05564169Masitinib in Patients With Mild Alzheimer's Disease
Phase 3Open Jobs (5)
Interview Prep Quick Facts
Portfolio: 46 clinical trials
Open Roles: 5 active jobs